spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Pradaxa 

 HSMN NewsFeed - 31 Jan 2018
Boehringer Ingelheim Announces Paul Fonteyne to Retire at the end of 2018. Wolfgang Baiker Appointed U.S. President & CEO Effective March 1, 2018
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jul 2014
Pradaxa(R) (dabigatran etexilate) Now Available in the UK for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and Prevention of Recurrence
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Sep 2013
Amakem Appoints Jean Marie Stassen as Vice President, Research and Development
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 28 Aug 2013
FDA Accepts Boehringer Ingelheim's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary Embolism
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Nov 2012
URGENT NOTICE -- DRUG RECALL: Boehringer Ingelheim Pharmaceuticals, Inc. Initiates a Voluntary Recall of a Single Manufacturing Lot of Pradaxa(R) (dabigatran etexilate mesylate) Capsules 75mg in the U.S. and Puerto Rico
Biopharmaceuticals Cardiology Product Recall
 HSMN NewsFeed - 26 Aug 2011
Boehringer Ingelheim to Launch RE-ALIGN Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Oct 2010
FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
Biopharmaceuticals Cardiology Neurology FDA
 HSMN NewsFeed - 20 Mar 2009
Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 Sep 2008
Nice Approves Pradaxa(R)*(Dabigatran Etexilate) - First New Oral Anticoagulant in the UK for Over 50 Years
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Mar 2008
Novel Oral Anticoagulant Pradaxa(R) (dabigatran etexilate) Approved by the European Commission
Biopharmaceuticals Regulatory
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.